SEARCH

SEARCH BY CITATION

References

  • 1
    Herr H, Dotan Z, Donat S et al. Defining optimal therapy for muscle invasive bladder cancer. J. Urol. 2007; 177: 437–443.
  • 2
    Raman JD, Messer J, Sielatycki JA et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011; 107: 1059–1064.
  • 3
    Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J. Urol. 2000; 164: 1523–5.
  • 4
    Brown GA, Busby JE, Wood CG et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? BJU Int. 2006; 98: 1176–80.
  • 5
    Margulis V, Shariat SF, Matin SF et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224–33.
  • 6
    Youssef RF, Shariat SF, Lotan Y et al. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 2011; 108: 128691.
  • 7
    Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull. Am. Coll. Surg. 2002; 87: 13–15.
  • 8
    Epstein JI, Amin MB, Reuter VR et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 1998; 22: 1435–8.
  • 9
    Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat. Clin. Pract. Urol. 2007; 4: 432–43.
  • 10
    Audenet F, Yates DR, Cussenot O et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol. Oncol. 2010. [Epub ahead of print]
  • 11
    Herr H, Sogani P. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 2001; 166: 1296–9.
  • 12
    Koukourakis G, Zacharias G, Koukourakis M et al. Comprehensive management of upper tract urothelial carcinoma. Adv. Urol. 2009. [Epub ahead of print]
  • 13
    Scolieri M, Paik M, Brown S. Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 2000; 56: 930–4.
  • 14
    Margulis V, Youssef RF, Karakiewicz PI et al. Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. J. Urol. 2010; 184: 453–8.
  • 15
    Kondo T, Nakazawa H, Ito F et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J. Urol. 2007; 178: 1212–17.
  • 16
    Kondo T, Nakazawa H, Ito F et al. Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology 2007; 69: 265–9.
  • 17
    Bolenz C, Shariat SF, Fernandez MI et al. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int. 2009; 103: 302–6.
  • 18
    Roscigno M, Cozzarini C, Bertini R et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur. Urol. 2008; 53: 794–802.
  • 19
    Roscigno M, Shariat SF, Margulis V et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J. Urol. 2009; 181: 2482–9.
  • 20
    Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003; 349: 859–66.
  • 21
    Droller M. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. J. Urol. 2000; 163: 16023.
  • 22
    Kikuchi E, Margulis V, Karakiewicz PI et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J. Clin. Oncol. 2009; 27: 612–18.
  • 23
    Matin SF, Margulis V, Kamat A et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116: 3127–34.
  • 24
    Igawa M, Urakami S, Shiina H et al. Neoadjuvant chemotherapy for locally advanced urothelial carcinoma of the upper urinary tract. Urol. Int. 1995; 55: 74–7.
  • 25
    Hellenthal NJ, Shariat SF, Margulis V et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J. Urol. 2009; 182: 900–6.